(XYL) Xylem - Overview
Stock: Pumps, Meters, Controls, Filtration, Analytics
| Risk 5d forecast | |
|---|---|
| Volatility | 35.7% |
| Relative Tail Risk | -8.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.02 |
| Alpha | -13.06 |
| Character TTM | |
|---|---|
| Beta | 0.859 |
| Beta Downside | 0.840 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.73% |
| CAGR/Max DD | 0.30 |
EPS (Earnings per Share)
Revenue
Description: XYL Xylem January 28, 2026
Xylem Inc. (NYSE: XYL) designs, manufactures, and services engineered water-related products for utility, industrial, residential, and commercial markets worldwide. The firm operates through four segments: Water Infrastructure; Applied Water; Measurement & Control Solutions; and Water Solutions & Services, delivering pumps, treatment equipment, smart meters, analytics software, and a suite of maintenance and remediation services under brands such as Flygt, Sensus, and Bell & Gossett.
In its most recent fiscal year (FY 2024), Xylem reported total revenue of $5.6 billion, up 6 % year-over-year, with the Measurement & Control Solutions segment posting a 12 % revenue growth driven by expanding smart-meter deployments. Adjusted EBITDA margin held at 15 %, and free cash flow reached $620 million, supporting continued dividend payouts and share-repurchase activity.
Key macro drivers remain robust: the global water-infrastructure market is projected to expand at a 5 % compound annual growth rate through 2030 as governments increase capital spending on climate-resilient water systems. Additionally, the U.S. EPA’s tightening of wastewater discharge standards is accelerating demand for Xylem’s advanced treatment and monitoring solutions, particularly in the Applied Water segment.
Given the breadth of Xylem’s product portfolio and its exposure to rising water-infrastructure spend, a deeper dive into segment-level forecasts may help assess upside potential-ValueRay’s analytics platform provides that granular view for further research.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 957.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.55 > 1.0 |
| NWC/Revenue: 19.76% < 20% (prev 20.53%; Δ -0.78% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.24b > Net Income 957.0m |
| Net Debt (463.0m) to EBITDA (1.22b): 0.38 < 3 |
| Current Ratio: 1.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (244.0m) vs 12m ago 0.08% < -2% |
| Gross Margin: 38.46% > 18% (prev 0.38%; Δ 3809 % > 0.5%) |
| Asset Turnover: 52.95% > 50% (prev 51.91%; Δ 1.04% > 0%) |
| Interest Coverage Ratio: 42.17 > 6 (EBITDA TTM 1.22b / Interest Expense TTM 29.0m) |
Altman Z'' 2.45
| A: 0.10 (Total Current Assets 4.64b - Total Current Liabilities 2.86b) / Total Assets 17.63b |
| B: 0.21 (Retained Earnings 3.71b / Total Assets 17.63b) |
| C: 0.07 (EBIT TTM 1.22b / Avg Total Assets 17.06b) |
| D: 0.59 (Book Value of Equity 3.49b / Total Liabilities 5.88b) |
| Altman-Z'' Score: 2.45 = A |
Beneish M -3.04
| DSRI: 1.00 (Receivables 1.76b/1.67b, Revenue 9.04b/8.56b) |
| GMI: 0.98 (GM 38.46% / 37.52%) |
| AQI: 0.98 (AQ_t 0.67 / AQ_t-1 0.68) |
| SGI: 1.06 (Revenue 9.04b / 8.56b) |
| TATA: -0.02 (NI 957.0m - CFO 1.24b) / TA 17.63b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of XYL shares?
Over the past week, the price has changed by -0.57%, over one month by -7.66%, over three months by -8.83% and over the past year by -0.90%.
Is XYL a buy, sell or hold?
- StrongBuy: 9
- Buy: 5
- Hold: 8
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the XYL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 160.4 | 25.1% |
| Analysts Target Price | 160.4 | 25.1% |
XYL Fundamental Data Overview February 14, 2026
P/E Forward = 22.9885
P/S = 3.3999
P/B = 2.69
P/EG = 1.938
Revenue TTM = 9.04b USD
EBIT TTM = 1.22b USD
EBITDA TTM = 1.22b USD
Long Term Debt = 1.41b USD (from longTermDebt, last quarter)
Short Term Debt = 534.0m USD (from shortTermDebt, last quarter)
Debt = 1.94b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 463.0m USD (from netDebt column, last quarter)
Enterprise Value = 31.18b USD (30.72b + Debt 1.94b - CCE 1.48b)
Interest Coverage Ratio = 42.17 (Ebit TTM 1.22b / Interest Expense TTM 29.0m)
EV/FCF = 34.26x (Enterprise Value 31.18b / FCF TTM 910.0m)
FCF Yield = 2.92% (FCF TTM 910.0m / Enterprise Value 31.18b)
FCF Margin = 10.07% (FCF TTM 910.0m / Revenue TTM 9.04b)
Net Margin = 10.59% (Net Income TTM 957.0m / Revenue TTM 9.04b)
Gross Margin = 38.46% ((Revenue TTM 9.04b - Cost of Revenue TTM 5.56b) / Revenue TTM)
Gross Margin QoQ = 38.88% (prev 38.93%)
Tobins Q-Ratio = 1.77 (Enterprise Value 31.18b / Total Assets 17.63b)
Interest Expense / Debt = 0.31% (Interest Expense 6.00m / Debt 1.94b)
Taxrate = 9.51% (35.0m / 368.0m)
NOPAT = 1.11b (EBIT 1.22b * (1 - 9.51%))
Current Ratio = 1.62 (Total Current Assets 4.64b / Total Current Liabilities 2.86b)
Debt / Equity = 0.17 (Debt 1.94b / totalStockholderEquity, last quarter 11.48b)
Debt / EBITDA = 0.38 (Net Debt 463.0m / EBITDA 1.22b)
Debt / FCF = 0.51 (Net Debt 463.0m / FCF TTM 910.0m)
Total Stockholder Equity = 11.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.61% (Net Income 957.0m / Total Assets 17.63b)
RoE = 8.59% (Net Income TTM 957.0m / Total Stockholder Equity 11.14b)
RoCE = 9.74% (EBIT 1.22b / Capital Employed (Equity 11.14b + L.T.Debt 1.41b))
RoIC = 8.50% (NOPAT 1.11b / Invested Capital 13.02b)
WACC = 8.56% (E(30.72b)/V(32.66b) * Re(9.08%) + D(1.94b)/V(32.66b) * Rd(0.31%) * (1-Tc(0.10)))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.52%
[DCF Debug] Terminal Value 79.47% ; FCFF base≈922.8m ; Y1≈1.14b ; Y5≈1.94b
Fair Price DCF = 118.9 (EV 29.43b - Net Debt 463.0m = Equity 28.97b / Shares 243.6m; r=8.56% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 89.70 | EPS CAGR: 34.29% | SUE: 0.22 | # QB: 0
Revenue Correlation: 92.12 | Revenue CAGR: 18.41% | SUE: 0.57 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.08 | Chg30d=-0.078 | Revisions Net=-1 | Analysts=17
EPS current Year (2026-12-31): EPS=5.50 | Chg30d=-0.047 | Revisions Net=-2 | Growth EPS=+8.4% | Growth Revenue=+1.8%
EPS next Year (2027-12-31): EPS=6.09 | Chg30d=-0.081 | Revisions Net=-1 | Growth EPS=+10.6% | Growth Revenue=+4.7%